P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS

Detalles Bibliográficos
Autores principales: Morè, S, Manieri, V M, Corvatta, L, Morsia, E, Rupoli, S, Olivieri, A, Offidani, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Poster
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011762/
http://dx.doi.org/10.1097/01.HS9.0000829672.61767.68
_version_ 1784687689529819136
author Morè, S
Manieri, V M
Corvatta, L
Morsia, E
Rupoli, S
Olivieri, A
Offidani, M
author_facet Morè, S
Manieri, V M
Corvatta, L
Morsia, E
Rupoli, S
Olivieri, A
Offidani, M
author_sort Morè, S
collection PubMed
description
format Online
Article
Text
id pubmed-9011762
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-90117622022-04-18 P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS Morè, S Manieri, V M Corvatta, L Morsia, E Rupoli, S Olivieri, A Offidani, M Hemasphere Poster Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC9011762/ http://dx.doi.org/10.1097/01.HS9.0000829672.61767.68 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Poster
Morè, S
Manieri, V M
Corvatta, L
Morsia, E
Rupoli, S
Olivieri, A
Offidani, M
P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
title P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
title_full P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
title_fullStr P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
title_full_unstemmed P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
title_short P25: CARFILZOMIB-BASED TREATMENTS COULD BE ADDED TO IMPEDE-VTE SCORE TO BETTER PREDICT VENOUS THROMBOEMBOLIC RISK IN MM PATIENTS
title_sort p25: carfilzomib-based treatments could be added to impede-vte score to better predict venous thromboembolic risk in mm patients
topic Poster
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011762/
http://dx.doi.org/10.1097/01.HS9.0000829672.61767.68
work_keys_str_mv AT mores p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients
AT manierivm p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients
AT corvattal p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients
AT morsiae p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients
AT rupolis p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients
AT olivieria p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients
AT offidanim p25carfilzomibbasedtreatmentscouldbeaddedtoimpedevtescoretobetterpredictvenousthromboembolicriskinmmpatients

Ejemplares similares